Ardelyx (41X) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

41X Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Ardelyx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

41X Stock 12 Month Forecast

Average Price Target

CHF10.95

▲(166.30% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is CHF10.95 with a high forecast of CHF14.46 and a low forecast of CHF7.23. The average price target represents a 166.30% change from the last price of CHF4.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"CHF3","6":"CHF6","9":"CHF9","12":"CHF12","15":"CHF15"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.45946894,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF14.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.945014683750001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF10.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.22973447,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF7.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6,9,12,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.108,4.904266841538461,5.700533683076923,6.496800524615384,7.293067366153846,8.089334207692307,8.885601049230768,9.68186789076923,10.47813473230769,11.274401573846152,12.070668415384613,12.866935256923075,13.66320209846154,{"y":14.45946894,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.108,4.633924206442307,5.159848412884616,5.685772619326923,6.211696825769231,6.737621032211538,7.263545238653846,7.789469445096154,8.31539365153846,8.84131785798077,9.367242064423078,9.893166270865386,10.419090477307693,{"y":10.945014683750001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.108,4.348133420769231,4.588266841538461,4.828400262307692,5.068533683076923,5.308667103846154,5.548800524615385,5.788933945384615,6.029067366153846,6.2692007869230775,6.509334207692308,6.749467628461539,6.989601049230769,{"y":7.22973447,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.108,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.108,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF14.46

Average Price TargetCHF10.95

Lowest Price TargetCHF7.23

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Nierengarten

Wedbush

CHF7.23

Buy

75.91%

Upside

Reiterated

08/18/26

Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), DocGo (NASDAQ: DCGO) and Ardelyx (NASDAQ: ARDX)

Allison Bratzel

Piper Sandler

CHF12.85→CHF12.05

Buy

193.18%

Upside

Reiterated

08/17/26

Ardelyx price target lowered to $15 from $16 at Piper SandlerArdelyx price target lowered to $15 from $16 at Piper Sandler

Unknown Analyst

Ladenburg Thalmann & Co.

Not Ranked

Ladenburg Thalmann & Co.

CHF12.85

Buy

212.72%

Upside

Reiterated

08/10/26

Ladenburg Thalmann & Co. Remains a Buy on Ardelyx (ARDX)

Yigal Nochomovitz

Citi

CHF11.25→CHF8.84

Buy

115.00%

Upside

Reiterated

08/10/26

Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)

Matthew Caufield

H.C. Wainwright

CHF14.46

Buy

251.81%

Upside

Reiterated

08/07/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Christopher Raymond

Raymond James

CHF15.26→CHF12.05

Buy

193.18%

Upside

Reiterated

08/07/26

Ardelyx price target lowered to $15 from $19 at Raymond JamesArdelyx price target lowered to $15 from $19 at Raymond James

Joseph Thome

TD Cowen

CHF10.44→CHF8.03

Buy

95.45%

Upside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)

Dennis Ding

Jefferies

CHF12.05

Buy

193.18%

Upside

Reiterated

06/26/26

Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'

Julian Harrison

BTIG

CHF13.66

Buy

232.27%

Upside

Reiterated

02/20/26

Ardelyx (ARDX) Receives a Buy from BTIG

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Nierengarten

Wedbush

CHF7.23

Buy

75.91%

Upside

Reiterated

08/18/26

Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), DocGo (NASDAQ: DCGO) and Ardelyx (NASDAQ: ARDX)

Allison Bratzel

Piper Sandler

CHF12.85→CHF12.05

Buy

193.18%

Upside

Reiterated

08/17/26

Ardelyx price target lowered to $15 from $16 at Piper SandlerArdelyx price target lowered to $15 from $16 at Piper Sandler

Unknown Analyst

Ladenburg Thalmann & Co.

Not Ranked

Ladenburg Thalmann & Co.

CHF12.85

Buy

212.72%

Upside

Reiterated

08/10/26

Ladenburg Thalmann & Co. Remains a Buy on Ardelyx (ARDX)

Yigal Nochomovitz

Citi

CHF11.25→CHF8.84

Buy

115.00%

Upside

Reiterated

08/10/26

Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)

Matthew Caufield

H.C. Wainwright

CHF14.46

Buy

251.81%

Upside

Reiterated

08/07/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Christopher Raymond

Raymond James

CHF15.26→CHF12.05

Buy

193.18%

Upside

Reiterated

08/07/26

Ardelyx price target lowered to $15 from $19 at Raymond JamesArdelyx price target lowered to $15 from $19 at Raymond James

Joseph Thome

TD Cowen

CHF10.44→CHF8.03

Buy

95.45%

Upside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)

Dennis Ding

Jefferies

CHF12.05

Buy

193.18%

Upside

Reiterated

06/26/26

Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'

Julian Harrison

BTIG

CHF13.66

Buy

232.27%

Upside

Reiterated

02/20/26

Ardelyx (ARDX) Receives a Buy from BTIG

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardelyx

3 Months

Yigal NochomovitzCiti

Success Rate

9/17 ratings generated profit

Average Return

+29.71%

Copying Yigal Nochomovitz's trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +29.71% per trade.

1 Year

Christopher RaymondRaymond James

Success Rate

8/17 ratings generated profit

Average Return

+22.21%

Copying Christopher Raymond's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +22.21% per trade.

2 Years

Christopher RaymondRaymond James

Success Rate

7/17 ratings generated profit

Average Return

+10.54%

Copying Christopher Raymond's trades and holding each position for 2 Years would result in 41.18% of your transactions generating a profit, with an average return of +10.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

41X Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 41X has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 41X average Analyst price target in the past 3 months is 10.95.

Each month's total comprises the sum of three months' worth of ratings.

41X Financial Forecast

41X Earnings Forecast

Next quarter’s earnings estimate for 41X is -CHF0.01 with a range of -CHF0.05 to CHF0.02. The previous quarter’s EPS was -CHF0.06. 41X beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 41X has Performed in-line its overall industry.

41X Sales Forecast

Next quarter’s sales forecast for 41X is CHF104.81M with a range of CHF97.02M to CHF109.10M. The previous quarter’s sales results were CHF98.05M. 41X beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 41X has Performed in-line its overall industry.

41X Stock Forecast FAQ

What is CH:41X’s average 12-month price target, according to analysts?

Based on analyst ratings, Ardelyx’s 12-month average price target is 10.95.

What is CH:41X’s upside potential, based on the analysts’ average price target?

Ardelyx has 166.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ardelyx a Buy, Sell or Hold?

Ardelyx has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ardelyx’s share price target?

The average share price target for Ardelyx is 10.95. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF14.46 ,and the lowest forecast is CHF7.23. The average share price target represents 166.30% Increase from the current price of CHF4.11.

What do analysts say about Ardelyx?

Ardelyx’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Ardelyx?

To buy shares of CH:41X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Ardelyx (41X) Stock Forecast & Price Target

41X Analyst Ratings

41X Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ardelyx

41X Analyst Recommendation Trends

41X Financial Forecast

41X Earnings Forecast

41X Sales Forecast

41X Stock Forecast FAQ

Detailed List of Analyst Forecasts